An interventional study of Stemregen in Male Infertility and Oligoasthenospermia, sponsored by Kocaeli University. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by Kocaeli University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Infertility, Male with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Infertility, Male · Turkey.
Among the 11 studies in Infertility, Male with a site in Turkey, this one is one of 2 that started in 2024, is one of 8 with no phase, and was the 11th registered.
282 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
Browse Infertility, Male studies →1 of the 11 studies in Infertility, Male with a site in Turkey is open now. Recruiting first, the newest first:
Medipol University · Sites in Turkey
Ages 18–45 · Men only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 40 Infertility, Male studies recruiting now, 16 (40%) set no upper age limit and 24 (60%) stop at 75 or younger; 7 take children under 18; 14 take healthy volunteers.
This study: 20 Years to 50 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 80 across 187 interventional studies indexed under Infertility, Male.
Median enrollment 80 across the 9 interventional studies, 70 across the 2 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
Kocaeli University is the lead sponsor of 215 studies on the registry; 39 are open to participants now.
Kocaeli University has 1 study filed under Infertility, Male — fewer than ten, so there is no comparison to draw.
1 of the studies in Infertility, Male with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07337265Medipol UniversityRoyal Jelly Supplementation in Unexplained Male Infertility | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Infertility, Male with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated whether Stemregen® dietary supplementation could improve sperm quality and assisted reproductive treatment outcomes in men with severe oligoasthenozoospermia who had previously experienced at least one failed intracytoplasmic sperm injection (ICSI) attempt. A total of 60 men were included and divided into a treatment group and a control group. Participants in the treatment group received Stemregen® dietary supplementation for 3 months, while the control group received no additional treatment. Semen parameters, sperm DNA fragmentation, fertilization, embryo transfer, and pregnancy outcomes were evaluated and compared between the groups.
Inclusion Criteria:men aged 20-50 years with severe oligoasthenozoospermia, defined for the purposes of the study as a sperm concentration \<5 × 10⁶/mL with markedly reduced progressive motility, and at least one previous unsuccessful intracytoplasmic sperm injection (ICSI) cycle. -
Exclusion Criteria: varicocele requiring surgical correction, obstructive azoospermia, hypogonadotropic hypogonadism, primary testicular failure, chromosomal abnormalities or known genetic causes of infertility, active genitourinary infection, uncontrolled diabetes mellitus, severe systemic disease, , previous chemotherapy or pelvic radiotherapy, and hormonal or antioxidant treatment within the preceding three months. Female partners underwent routine infertility evaluation, and couples with severe female infertility factors, including diminished ovarian reserve, advanced endometriosis, major uterine abnormalities, or severe ovulatory dysfunction
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants received standard-dose Stemregen®dietary supplementatıon for 3 months
Dietary Supplement: Stemregen
participants received no additional treatment during the study period
participants received standard-dose Stemregen® dietary supplementatıon for 3 months
Change in Sperm Count
Change in Sperm Count from baseline to after 3 months of Stenregen supplementation,assessed by semen analysis
Time frame: Baseline and 3 months
Ran from Oct 2024 to primary completion in Mar 2026, 17 months.
Of 77 non-industry interventional studies with no phase under Infertility, Male, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 17 months is below that.
Counting every sponsor, half of 92 studies reached it within 34 months; a quarter within 17 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.